Entera Bio Ltd. (ENTX) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-05-08

Entera Bio Ltd. (ENTX) has filed 3 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-08. 1 Form 8-K material event filings were reported by ENTX in the last 90 days. InsiderAlpha tracks every ENTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Entera Bio Ltd. (ENTX)

SEC CIK	0001638097

90-Day SEC Filing Activity

Form 4 filings (90d)	3
Form 8-K filings (90d)	1
Latest Form 4 filing	2026-05-08

Recent ENTX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-05-07	Burshtein Gregory	Chief of R&D	A — Grant or award	87.6K	$0.00	—	SEC
2026-05-07	Yaacov-Garbeli Dana	Chief Financial Officer	A — Grant or award	58.4K	$0.00	—	SEC
2026-05-07	Galitzer Hillel	Chief Operating Officer	A — Grant or award	73.0K	$0.00	—	SEC
2026-03-09	Germano Geno J	Director	P — Open-market purchase	20.0K	$1.30	$26K	SEC
2026-03-05	Ellis Sean	Director	P — Open-market purchase	10.0K	$1.23	$12K	SEC
2026-02-12	Rubin Steven D	Director	P — Open-market purchase	5.0K	$1.49	$7K	SEC
2026-02-10	Germano Geno J	Director	P — Open-market purchase	20.0K	$1.49	$30K	SEC
2026-02-10	Taitel Haya	Director	P — Open-market purchase	7.5K	$1.48	$11K	SEC
2026-02-09	Rubin Steven D	Director	P — Open-market purchase	10.0K	$1.20	$12K	SEC
2026-02-09	Ellis Sean	Director	P — Open-market purchase	18.0K	$1.24	$22K	SEC
2026-01-01	Ellis Sean	Director	A — Grant or award	25.4K	$0.00	—	SEC
2026-01-01	OSTROV GERALD M	Director	A — Grant or award	28.7K	$0.00	—	SEC
2026-01-01	Malca Yonatan	Director	A — Grant or award	30.2K	$0.00	—	SEC
2026-01-01	LIEBERMAN GERALD M	Director	A — Grant or award	38.3K	$0.00	—	SEC
2026-01-01	Taitel Haya	Director	A — Grant or award	26.3K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Entera Bio Ltd. (ENTX). Updated in real time as new filings are submitted to the SEC.

Most-Active ENTX Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Yaacov-Garbeli Dana	1	—
Burshtein Gregory	1	—
Galitzer Hillel	1	—

Recent ENTX Form 8-K Material Events

2026-05-08 — Item 2.02, 7.01, 9.01 [SEC]
2026-04-03 — Item 1.01, 3.02, 9.01 · Financing · positive [SEC]
Entera Bio completed a private placement of 7.8 million units with BVF Partners LP for approximately $10.0 million gross proceeds ($1.2775 per unit), with each unit consisting of one ordinary share (or pre-funded warrant) and one warrant to purchase 1.5 ordinary shares. The closi
2026-03-27 — Item 2.02, 7.01, 9.01 · Earnings · neutral [SEC]
Entera Bio Ltd. issued a press release on March 27, 2026 announcing its financial results for the year ended December 31, 2025 and business updates. The filing provides standard annual financial results and operational updates without explicit beat/miss or guidance language.
2026-03-04 — Item 7.01, 9.01 · Clinical · positive [SEC]
Entera Bio submitted a Phase 3 protocol to the FDA to initiate a registrational trial of EB613 in postmenopausal women with osteoporosis. This represents a significant milestone in the clinical development of the company's lead candidate, advancing toward potential regulatory app

Recent Insider Filings

2026-05-08 — Galitzer Hillel (Chief Operating Officer)
2026-05-08 — Yaacov-Garbeli Dana (Chief Financial Officer)
2026-05-08 — Burshtein Gregory (Chief of R&D)
2026-03-11 — Germano Geno J (Director)
2026-03-09 — Ellis Sean (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ENTX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

ENTX Insider Trading — FAQ

What is the latest insider trade for ENTX?: Entera Bio Ltd. (ENTX) had 3 insider filings in the last 90 days, with the most recent on 2026-05-08. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying ENTX stock?: 0 insider purchases of ENTX were filed in the last 90 days.
How many insiders are selling ENTX stock?: 0 insider sales of ENTX were filed in the last 90 days.
Where can I see ENTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every ENTX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live ENTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.